Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications-Reference-Cited by-同舟云学术

Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications

Published:2010-06-09 Issue: Volume:16 Page:13-17
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

SANTAGOSTINO E.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02301.x/fullpdf

Reference28 articles.

1. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children;Pergantou;Haemophilia,2006

2. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis;White;Thromb Haemost,2001

3. National Hemophilia Foundation MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007

4. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

5. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group;Aledort;J Intern Med,1994

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding;Journal of Thrombosis and Haemostasis;2023-12

2. Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients;Journal of Thrombosis and Haemostasis;2021-03-24

3. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa;PLOS ONE;2020-10-28

4. Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly;Reports — Medical Cases, Images, and Videos;2020-01-27

5. The benefits of prophylaxis in patients with hemophilia B;Expert Review of Hematology;2018-07-18